Literature DB >> 28471829

Epidemiology of pancreatic cancer in France: descriptive study from the French national hospital database.

Frédérique Maire1, Jean-Olivier Cibot, Catherine Compagne, Olivia Hentic, Pascal Hammel, Nelly Muller, Philippe Ponsot, Philippe Levy, Philippe Ruszniewski.   

Abstract

INTRODUCTION: Although indirect evidence suggests that the incidence of pancreatic adenocarcinoma has increased in the last decade, few data are available in European countries. The aim of the present study was to update the epidemiology of pancreatic cancer in France in 2014 from the French national hospital database (Programme de Médicalisation des Systèmes d'Information). PATIENTS AND METHODS: All patients hospitalized for pancreatic cancer in France in 2014 in public or private institutions were included. Patient and stays (length, type of support, institutions) characteristics were studied. The results were compared with those observed in 2010.
RESULTS: A total of 13 346 (52% men, median age 71 years) new patients were treated for pancreatic cancer in 2014, accounting for a 12.5% increase compared with 2010. Overall, 22% of patients were operated on. Liver metastases were present in 60% of cases. The disease accounted for 146 680 hospital stays (+24.8% compared with 2010), 76% of which were related to chemotherapy (+32%). The average annual number and length of stay were 7 and 2.6 days, respectively. In 2014, 11 052 deaths were reported (+15.8%).
CONCLUSION: Approximately 13 350 new cases of pancreatic cancer were observed in France in 2014. The increase in incidence was associated with a marked increase in hospital stays for chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28471829     DOI: 10.1097/MEG.0000000000000901

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  6 in total

1.  Bromelain and acetylcysteine (BromAc®) alone and in combination with gemcitabine inhibit subcutaneous deposits of pancreatic cancer after intraperitoneal injection.

Authors:  Ahmad H Mekkawy; Krishna Pillai; Hyerim Suh; Samina Badar; Javed Akhter; Vahan Képénékian; Kevin Ke; Sarah J Valle; David L Morris
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

2.  Risk Assessment of Liver Metastasis in Pancreatic Cancer Patients Using Multiple Models Based on Machine Learning: A Large Population-Based Study.

Authors:  Qinggang Li; Lu Bai; Jiyuan Xing; Xiaorui Liu; Dan Liu; Xiaobo Hu
Journal:  Dis Markers       Date:  2022-05-18       Impact factor: 3.464

Review 3.  An update on treatment options for pancreatic adenocarcinoma.

Authors:  Aurélien Lambert; Lilian Schwarz; Ivan Borbath; Aline Henry; Jean-Luc Van Laethem; David Malka; Michel Ducreux; Thierry Conroy
Journal:  Ther Adv Med Oncol       Date:  2019-09-25       Impact factor: 8.168

4.  Current Role of Surgery in Pancreatic Cancer With Synchronous Liver Metastasis.

Authors:  Wentao Zhou; Dansong Wang; Wenhui Lou
Journal:  Cancer Control       Date:  2020 Jan-Dec       Impact factor: 3.302

5.  Time-frequency analysis of serum with proton nuclear magnetic resonance for diagnosis of pancreatic cancer.

Authors:  Asahi Sato; Toshihiko Masui; Akitada Yogo; Takashi Ito; Keiko Hirakawa; Yoshimasa Kanawaku; Kaoru Koike; Shinji Uemoto
Journal:  Sci Rep       Date:  2020-12-14       Impact factor: 4.379

6.  [Cancers of the pancreas at the National Hospital and University Center of Cotonou: epidemiological, diagnostic, therapeutic and prognostic features].

Authors:  Aboudou Raïmi Kpossou; Dansou Gaspard Gbessi; Freddy Houéhanou Rodrigue Gnangnon; Meissarath Modoukpè Ba Boukari; Rodolph Koffi Vignon; Comlan N Déhougbéa Martin Sokpon; Jean Sehonou
Journal:  Pan Afr Med J       Date:  2021-05-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.